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Dysfunction of the apelinergic system, comprised of the neuropeptide apelin mediating
its effects via the G protein-coupled apelin receptor (APJ), may underlie the onset
of cardiovascular disease such as hypertension. Apelin expression is increased in
the rostral ventrolateral medulla (RVLM) in spontaneously hypertensive rats (SHRs)
compared to Wistar-Kyoto (WKY) normotensive rats, however, evidence that the
apelinergic system chronically influences mean arterial blood pressure (MABP) under
pathophysiological conditions remains to be established. In this study we investigated,
in conscious unrestrained rats, whether APJ contributes to MABP and sympathetic
vasomotor tone in the progression of two models of hypertension – SHR and L-
NAME-treated rats – and whether APJ contributes to the development of hypertension
in pre-hypertensive SHR. In SHR we showed that APJ gene (aplnr) expression was
elevated in the RVLM, and there was a greater MABP increase following microinjection
of [Pyr1]apelin-13 to the RVLM of SHR compared to WKY rats. Bilateral microinjection
of a lentiviral APJ-specific-shRNA construct into the RVLM of WKY, SHR, and L-NAME-
treated rats, chronically implanted with radiotelemeters to measure MABP, decreased
aplnr expression in the RVLM and abolished acute [Pyr1]apelin-13-induced increases
in MABP. However, chronic knockdown of aplnr in the RVLM did not affect MABP in
either SHR or L-NAME-treated rats. Moreover, knockdown of aplnr in the RVLM of
prehypertensive SHR did not protect against the development of hypertension. These
results show that endogenous apelin, acting via APJ, is not involved in the genesis or
maintenance of hypertension in either animal model used in this study.
Keywords: apelin receptor, apelin, blood pressure, rostral ventrolateral medulla, hypertensive rats
INTRODUCTION
The brainstem plays a vital role in blood pressure (BP) regulation through an intricate signaling
network that modulates sympathetic nerve activity (SNA) and secretes hormones into the
circulation to maintain a homeostatic BP (Fisher and Paton, 2012). Increasing evidence supports
a role for the neuropeptide apelin as a key regulator of central and peripheral responses to
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homeostatic perturbations including the control of fluid
homeostasis (O’Carroll and Lolait, 2003), food intake (Taheri
et al., 2002) and angiogenesis (Liu et al., 2015). Apelin also has
an important role in the maintenance of basic cardiac function,
inducing a potent positive inotropic effect in isolated rat heart
(Szokodi et al., 2002) and maintaining cardiac contractility with
aging and pressure overload (Kuba et al., 2007). Additionally,
apelin contributes to cardiovascular pathological processes such
as heart failure (Földes et al., 2003), coronary heart disease (see Yu
et al., 2014 for review) and hypertension (Lee et al., 2005; Zhang
et al., 2009, 2014; Barnes et al., 2013). The specific role of the
apelinergic system in neural control of cardiovascular function
however, remains unclear.
Apelin (gene name apln), primarily synthesized as a 77-
amino acid prepropeptide precursor (Tatemoto et al., 1998),
is cleaved into a shorter biologically active 36 amino-acid
peptide. Unlike most other G protein-coupled (GPCR) families,
apelin appears to mediate its effects via binding to only one
receptor subtype, the apelin receptor (APJ; gene name aplnr).
Other isoforms of the apelin peptide are also agonists at
APJ (Habata et al., 1999; Zou et al., 2000; Medhurst et al.,
2003), including apelin-12, -13, and the pyroglutamyl form
of apelin-13 ([Pyr1]apelin-13) that may be the most potent
biological ligand (Tatemoto et al., 1998; Habata et al., 1999).
The apelinergic system is richly expressed in central neural
circuits that are involved in the modulation of BP, including
the medial parvocellular paraventricular nucleus (PVN) (Lee
et al., 2000; O’Carroll et al., 2000), the cerebroventricular
system, and lower brainstem structures such as the rostral
ventrolateral medulla (RVLM) (Lee et al., 2000; Brailoiu
et al., 2002; Reaux et al., 2002). Therefore apln and aplnr
transcripts are expressed in discrete brain regions that position
them to be potential chronic modulators of cardiovascular
tone.
While studies support apelin acting peripherally as an
anti-hypertension factor (Zhong et al., 2005; Sonmez et al.,
2010; Chandra et al., 2011; Zhu et al., 2013), neurological
pathways profoundly influence peripheral homeostatic systems,
and centrally administered [Pyr1]apelin-13 [the predominant
apelin isoform in the cardiovascular system (Maguire et al.,
2009)] has been shown to increase mean arterial blood pressure
(MABP) in normotensive rats (Seyedabadi et al., 2002; Kagiyama
et al., 2005; Zhang et al., 2009; Griffiths et al., 2017). Compelling
evidence suggests that elevated SNA is key in the development
of hypertension (Grassi, 1998; Fisher and Paton, 2012), and in
the spontaneously hypertensive rat (SHR) model of hypertension,
SNA is higher than in its normotensive control the Wistar-
Kyoto (WKY) rat (Cabassi et al., 2002; Simms et al., 2009).
Importantly, central administration of [Pyr1]apelin-13 is known
to affect sympathetic tone in addition to MABP (Seyedabadi et al.,
2002; Zhang et al., 2009; Griffiths et al., 2017), increasing SNA by
mechanisms that are not understood.
The neural control of BP is mediated in part via the activity
of barosensitive sympathetic efferents, set by a core network of
neurons including the RVLM, the PVN and the nucleus of the
solitary tract (Guyenet, 2006). A number of reports implicate
apelin in the regulation of RVLM increases in SNA and MABP.
In the RVLM of WKY rats, overexpression of apln using adeno-
associated virus type 2 vector-mediated gene transfer results
in a chronic elevation in BP in conscious rats (Zhang et al.,
2009), and acute microinjection of apelin-13 increases BP, SNA
and heart rate (HR) (Seyedabadi et al., 2002; Zhang et al.,
2009) in anesthetized rats. Additionally, apelin protein levels and
apln expression is enhanced in the RVLM of SHR compared
with WKY rats, and microinjection of an apelin-neutralizing
antibody into the RVLM lowers BP in anesthetized SHR but
not in normotensive rats (Zhang et al., 2009), suggesting that
apelin is sympathoexcitatory in this region. Moreover we have
recently shown that bilateral microinjection of [Pyr1]apelin-13
into the RVLM increases BP and sympathetic vasomotor tone (as
indirectly measured by spectral analysis of BP) in anesthetized
Wistar rats (Griffiths et al., 2017).
As recent reports imply that central apelin-13 may contribute
to BP regulation and play a causative role in neurogenic
hypertension, we hypothesized that APJ signaling in the RVLM
may contribute to the development of hypertension through
regulation of SNA and that targeting this central APJ pathway
may be an important new strategy in modulating sympathetic
outflow to reverse or prevent hypertensive pathology. Therefore,
the aim of the present study was to determine whether
knockdown of APJ activity in the RVLM of hypertensive rat
models acts to depress sympathetic vasomotor tone and arterial
pressure. We tested this hypothesis using chronic knockdown
of the RVLM APJ by lentiviral APJ-specific-small hairpin RNA
(LV-APJ-shRNA) mediated gene transfer in SHR, a genetic
model of essential hypertension, and Nω-Nitro-L-arginine
methyl ester hydrochloride (L-NAME)-induced hypertensive
rats, adopting radiotelemetry for long-term monitoring of
multiple cardiovascular variables. We also explored whether
knockdown of APJ activity in the RVLM of juvenile pre-
hypertensive SHR, and thus disruption of the apelinergic system
early in development, acts to prevent the onset of hypertension in
this model.
MATERIALS AND METHODS
Ethical Approval
All experiments were approved by the University of Bristol
Animal Welfare and Ethical Review Body and performed in
strict accordance with United Kingdom. Home Office regulations
[Animals (Scientific Procedures) Act (1986)].
Animals
Male WKY rats (WKY; n = 36; 225–250 g; Envigo,
United Kingdom), adult SHRs(n = 16; 225–250 g; Animal
Services Unit, University of Bristol, United Kingdom) and
juvenile SHRs (n = 20; 90 g; Animal Services Unit, University of
Bristol, United Kingdom) were housed at a constant temperature
(21 ± 2◦C) and humidity on a 14:10 h light:dark cycle. The
light cycle was set as 0500 h lights on and 1900 h lights off.
Access to standard laboratory chow and water was provided
ad libitum. For the generation of the L-NAME hypertension
model, where chronic oral administration of the nitric oxide
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synthase (NOS) inhibitor promotes persistent hypertension via
overactivity of the central sympathetic nervous system (Sander
and Victor, 1999; Zanzinger, 1999), blockade of NO was induced
in a group of WKY rats (n = 6; 120 g) by oral administration of
L-NAME (daily intake 50 mg kg−1 for 3 weeks; Sigma Aldrich,
United Kingdom) in the drinking water to induce hypertension,
followed by a maintenance dose (10 mg kg−1) (Guarasci and
Kline, 1996; Paulis et al., 2008). Doses were calculated for
each singly housed animal on the assumption that rats drink
approximately 10 ml/100 g/day (Greenwood et al., 2015).
Chronic Arterial Blood Pressure
Measurement
Femoral Vein Cannulation
Intravenous (i.v.) cannulas were constructed by welding a
3 cm length of MRE033 (OD: 0.033,” Braintree Scientific,
United Kingdom) to an 18 cm length of MRE040 tubing
(OD: 0.040,” Braintree Scientific, United Kingdom). Cannula
tips were coated with Tridodecylmethylammonium Chloride
Heparin Complex (2% w/w; Polysciences Inc., United States).
Adult WKY (n = 12), L-NAME treated WKY (n = 12)
and SHR (n = 12) were anesthetized with isoflurane (4%
for induction and 2% for maintenance in O2) and analgesia
administered (Vetergesic; 0.8 mg kg−1). Cannulas were tunneled
subcutaneously and connected at the level of the scapulas to
an externalized deburred 23G needle (Coopers Needle Works,
United Kingdom) that had been mounted on a 1 cm2 piece
of polypropylene mesh (Small Parts Ltd., United States) at the
level of the scapulas. On completion of surgery, rats were singly
housed in a soundproofed room. Cannulas were flushed with
0.5 ml heparinized saline (50 IU ml−1) daily for 1 week following
surgery and then every other day for the remainder of the
experiment.
Telemeter Implantation
A radiotelemetry system (TRM54P, Millar, Houston, TX,
United States) was adopted to make chronic, continuous
measurements of arterial pressure as reported previously
(McBryde et al., 2013). Rats underwent telemetry surgery 3 days
following i.v. cannulation. Rats were anesthetized with isoflurane
(as above), analgesia administered (as above), and the telemeter
catheter was advanced ∼1.5 cm into the descending aorta
in the peritoneal cavity above the level of the caudal aorta
bifurcation. A small volume of Vetbond (WPI, United Kingdom)
tissue adhesive was applied to the site of catheter entry to
prevent blood leakage and the catheter was held in place
using a 2 × 1 cm patch of plastic surgical mesh (Millar,
New Zealand). The body of the telemeter was secured within
the peritoneal cavity using non-absorbable suture material (3–
0 Mersilk, Ethicon, United Kingdom). Following telemeter
implantation animals were allowed 5 days recovery before
blood pressure recording began. Blood pressure was recorded
continuously for 5 days before (baseline) and 25 days after
virus injection surgeries. Telemeters were kept charged within
animals and blood pressure signals received by SmartPads
(TR180; Millar). The experimental room was acoustically
isolated.
Gene Transfer Into the RVLM
Lentiviral Vector Generation
To produce APJ-specific knockdown, rats were transduced
with a lentivirus (LV) containing short hairpin interfering
RNA (shRNA) targeting the rat APJ sequence. The APJ-
specific shRNA construct was generated by PCR using
the pSilencer vector (10 ng), the M13 forward primer, and
reverse primers designed against rat APJ (GenBank Accession
NM_031349). Following amplification, the PCR product
was cloned directly into the TOPO TA intermediate vector
(Invitrogen, United Kingdom), transformed into TOP10 One
Shot Cells (Invitrogen, United Kingdom), and clones selected
and analyzed using restriction enzyme digestion with Xho1,
and DNA sequencing. The APJ shRNA (LV-APJ-shRNA)
and a scrambled control shRNA (LV-scr-shRNA), consisting
of the same nucleotides in the shRNA but in random order
and not matched to any other rat gene, were excised from
pSilencer vector and expressed in the lentiviral transfer vector
pRRL.SIN.CPPT.CMV.GFP.WPRE, allowing targeting of
both C1 and non-C1 neurons. The lentiviral transfer vectors
pRRL.SIN.CPPT.CMV.GFP. WPRE (used for determination
of transduction efficiency and as a control) and pRRL.SIN.
CPPT.CMV.APJ/SCR. WPRE and all packaging plasmids
(pMDLg/pRRE, pRSV-Rev, PMD2.G; Addgene) were propagated
in Stbl3 competent cells to reduce homologous recombination.
All plasmid constructs were purified by Maxiprep using a
PureLink HiPure Plasmid Filter Maxiprep kit (Invitrogen).
Viruses were generated by transient transfection of the
transfer vector together with 3 separate packaging plasmids
into HEK293T/17 cells by the calcium phosphate method as
previously described (Panyasrivanit et al., 2011). Purified virus
was resuspended in prewarmed PBS (150 µl) and stored at
−80◦C. Viral titers were determined by counting GFP-positive
cells at day 3 following infection of HEK293T cells. The effective
time point after virus transfection into the RVLM was determined
by a time course (16, 25, and 30 days; n = 9) measuring loss of
[Pyr1]apelin-13-induced cardiovascular effects in the RVLM and
was found to be maximal at 25 days.
Intraparenchymal Injection of Lentivirus
Ten days post telemeter implantation rats were anesthetized
with an intramuscular injection of ketamine (60 mg kg−1)
and medetomidine (250 µg kg−1) and analgesia administered
(Vetergesic 0.8 mg kg−1). Rats were placed in a stereotaxic
frame with the head flexed down (nose bar at −19 mm). The
dorsal brainstem was exposed following partial retraction of
the occipital bone and atlanto-occipital membrane. Lentivirus
injections to the RVLM were made using single-barreled
micropipettes (1–5 µl calibrated microcapillary tube, Sigma
Aldrich, United Kingdom), angled at 20◦ rostral and aligned with
the caudal point of the obex as the reference with the aid of a
binocular surgical microscope (Leica M651, United Kingdom).
The RVLM was targeted using the following stereotaxic co-
ordinates: 0.18 cm lateral from midline, 0.12 cm rostral and
0.35 cm ventral for adult rats (>250 g) and 0.17 cm lateral,
0.09 cm rostral and 0.30 cm ventral for juvenile rats (∼90 g). The
micropipette was advanced to the correct depth and allowed to
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rest for 5 min (min) prior to viral vector (1 µl, lentiviral titres:
LV-APJ-shRNA, 1.12× 1010 pfu ml−1; LV-scr-shRNA, 4.3× 109
pfu ml−1) injection over a period of 10 min. The pipette was
then left in situ for a further 5 min to ensure the virus remained
at the correct depth in the brainstem. This was then repeated
to target the contralateral RVLM. Anesthesia was reversed by a
subcutaneous injection of Antisedan (1 mg kg−1). Rats received
injection of either LV-scr-shRNA or LV-APJ-shRNA (n = 6
group−1). Blood pressure recording continued for 25 days (see
data acquisition below). The level of APJ gene knockdown was
confirmed by quantitative PCR (qPCR) (see below).
Pharmacological Manipulation of the
RVLM
Confirmation of Chronic APJ Knockdown by Femoral
Artery Blood Pressure Recording
Twenty five days post-virus injection a terminal, non-recovery,
experiment was carried out to test for the long term expression
of the transgene and to confirm that chronic knock-down of
APJ blocked MABP responses following a direct “challenge”
microinjection of [Pyr1]apelin-13 to the RVLM (Griffiths et al.,
2017). Rats were anesthetized with sodium pentobarbital (50 mg
kg−1 i.p.) and BP was monitored via a heparin-saline (1 U
ml−1) filled catheter (Micro-Renathane tubing, 0.033” inner
diameter, Braintree Scientific, MA, United States) implanted in
the left femoral artery and connected to a pressure transducer
(BD DTX Plus, Southwest Medical, Bristol, United Kingdom).
Pressure signals were amplified and filtered using a NeuroLog
System (Digitimer, Welwyn Garden City, United Kingdom).
RVLM injections followed the same protocol described above for
virus injections. The pressor response to bilateral microinjection
of L-glutamate (1 nmol 100 nl−1 side−1; Tocris Bioscience,
United Kingdom) was used to confirm the position of the
pipette within the RVLM. Subsequent bilateral microinjections
of [Pyr1]apelin-13 (200 pmol 100 nl−1; Bachem, Germany)
were made at the same stereotaxic coordinates that elicited
the largest L-glutamate pressor response (>20 mmHg). After
the final L-glutamate microinjection, rats were euthanized
using a guillotine. Brains were immediately frozen on
powdered dry ice and stored at −80◦C to preserve RNA
integrity.
Acute Pharmacological Blockade of APJ in the RVLM
of Anesthetized WKY and SHR
The RVLM of WKY (n = 4) and SHR (n = 4) rats was
targeted bilaterally using the coordinates described previously
(Griffiths et al., 2017). The position of the micropipette in
the RVLM was first confirmed by a bilateral injection of
L-glutamate (1 nmol 100 nl−1 side−1). Drug solutions were
prepared according to the manufacturer’s instructions, diluted
to the required concentration (consistent with a large body
of literature on the physiological effects of drugs used in
the RVLM and other brain regions (Seyedabadi et al., 2002;
Zhang et al., 2009; Huber and Schreihofer, 2011; Zhang et al.,
2014) in normal saline, and stock aliquots were stored at
−20◦C until thawed for use. Bilateral drug microinjections
of 100 nl then progressed as follows; saline, [Pyr1]apelin-13
(200 pmol, 100 nl−1; Bachem, Germany), [Ala13]apelin-13
(F13A, 2 nmol, Phoenix Pharmaceuticals, Belmont, CA,
United States), [Pyr1]apelin-13 (200 pmol, 100 nl−1), saline.
A repeat injection of F13A was made ∼45 min after initial F13A
injection to test any response to injection of the antagonist.
Animals received a microinjection of Indian ink (100 nl;
1:10 dilution) at the end of the experiment to confirm the
histological location of the micropipette within the RVLM.
Animals received an anesthetic overdose and were euthanized
by decapitation. Brains were removed, immediately frozen
on dry ice and stored at −80◦C. Hindbrains were cut at
40 µm using a cryostat (CM3050 S, Leica Microsystems)
to reveal the position of ink injection relative to the
RVLM.
Tail Cuff Blood Pressure Measurement
The tail arterial systolic blood pressure was determined in
juvenile SHR (90 g; n = 12) with a tail-cuff sphygmomanometer
(CODA2 Tail Cuff Blood Pressure System; Kent Scientific,
United States). Three days after stereotaxic surgery to administer
LV-APJ-shRNA (n = 6) or LV-scr-shRNA (n = 6), 4-week-old
juvenile SHR were acclimatized to the restraint holders, occlusion
cuff, and volume pressure cuff, for between 20 and 30 min
each day over the course of a week. Data acquisition was then
carried out twice a week until 6 weeks after virus microinjection
into the RVLM. During recording sessions rats were placed
in restraint holders and the tail warmed on a warming pad
for 15 min to bring the tail temperature to between 30 and
35◦C (to increase blood flow and improve data acquisition).
A full recording session consisted of 10 acclimatization cycles
to optimize data acquisition, followed by 15 data acquisition
cycles during which systolic, diastolic and mean arterial BP were
monitored.
RNA Extraction and cDNA Synthesis
Fresh, frozen sections (40 µm) were cut on a cryostat
(CM3050 S, Leica Microsystems) moving in the caudal-rostral
direction through the brainstem and collected on the freezing
plate. Every fifth section was stained with 0.1% toluidine
blue to aid in the identification of the RVLM. The RVLM
is situated just caudal of the facial nucleus and as such
punches were taken from the 4 sections immediately prior
to the section that was first identified as having large facial
nucleus cell bodies. Left and right RVLM were punched
out using a 1 mm diameter micropunch (Fine Scientific
Tools) and placed into separate 1.5 ml RNAse/DNAse-
free tubes (Appleton Woods, United Kingdom) on dry
ice and stored at −80◦C, before RNA extraction. Samples
were mechanically homogenized in Trizol and processed
for RNA isolation and purification using the Trizol Plus
RNA purification kit (Applied Biosystems, United Kingdom),
according to the manufacturer’s instructions. RNA yield was
measured using a Nanodrop System (Thermo Fisher Scientific,
United Kingdom). For cDNA synthesis 80 ng of total RNA
was treated with DNase I, to eliminate genomic DNA from
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the sample, prior to reverse transcription using the High
Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems,
United Kingdom).
Real Time qPCR Analysis
Primers for aplnr (5′-GCTCCCAGAGAGGCTAGTTCTG-
3′ and 5′-TGGAGGCTTGGCTCAAACC-3′, bp 59–80
and 125–143, respectively, of GenBank accession
NM_031349), apln (5′-TTCTAAAGCAGGATTGAAGGGC-3′
and 5′-CCATCAGCAGCGATAACAGG-3′, bp 569–
590 and 682–701, respectively, of GenBank accession
NM_031612) and the internal control housekeeping genes
ribosomal protein L19 (5′-GCGTCTGCAGCCATGAGTA-
3′ and 5′-TGGCATTGGCGATTTCGTTG-3′) and
GAPDH (5′-ATGATTCTACCCACGGCAAG-3′ and 5′-
CTGGAAGATGGTGATGGGTT-3′) were optimized and
validated using standard ABI protocols. The cDNA from
the reverse transcription procedure was used as template for
quantitative PCR, which was carried out in duplicate in 10 µl
reaction volumes using SYBR green master mix buffer (Applied
Biosystems, United Kingdom). Plates (MicroAmp Fast 96-Well
Reaction Plate (0.1 ml), Applied Biosystems, United Kingdom)
were run for 45 cycles of 95◦C for 15 s and 60◦C for 1 min
on a StepOnePlus real-time PCR system (Applied Biosystems,
United Kingdom). All qRT-PCR reactions were followed by
dissociation curve analysis. Relative quantification of gene
expression was performed using the 211CT method (Livak and
Schmittgen, 2001).
Immunohistochemistry
WKY rats (n = 2 per group) were terminally anesthetized
25 days after virus injection using sodium pentobarbital (50 mg
kg−1 i.p.) prior to transcardial perfusion with 4% (w/v)
paraformaldehyde (PFA) in phosphate-buffered saline (PBS, pH
7.4). Brains were removed, post-fixed overnight in 4% (w/v)
PFA, cryoprotected in 30% (w/v) sucrose in PBS at 4◦C, flash
frozen on liquid nitrogen and stored at −80◦C. Sections were
cut at 40 µm on a cryostat and transferred to a 24 well
plate containing 1 ml PBS in each well. Every fifth section
was used to confirm the expression of GFP within the RVLM.
Immunohistochemical staining was performed using the free-
floating method on at least 15 sections with no more than
five brainstem sections per well. Sections were washed with
PBS and then blocked with PBS containing 3% BSA/0.3%
Triton X-100. Following blocking, sections were incubated
with anti-GFP primary antibody (1:3000, rabbit polyclonal,
AB290, Abcam, United Kingdom) in PBS/3% BSA/0.3% Triton
X-100 at 4◦C for 48 hrs, followed by secondary antibody
(1:500, goat anti-rabbit AlexaFluor 488, A-11008, Thermo Fisher
Scientific, United Kingdom, in 1% BSA, 0.3% Triton, PBS)
at room temperature for 1 h. Sections were counterstained
with DAPI (1:1000 of 1 mg/ml in PBS), mounted onto slides
subbed with 0.5% (w/v) gelatin in dH2O, allowed to dry, and
coverslipped using ProLong Gold antifade reagent (Life Tech,
United Kingdom). Images were captured on an epifluorescence
microscope (DMI6000 Leica Microsystems).
Data Acquisition and Analysis
All blood pressure signals were recorded using a 1401 data
acquisition system and Spike 2 version 7.14 (Cambridge
Electronic Design, United Kingdom) digitized at 5 kHz. Baseline
values of physiological variables, including diastolic arterial blood
pressure (DABP), systolic arterial blood pressure (SABP), MABP,
pulse interval (PI), respiratory rate (RR) and HR, were recorded
and averaged over 5 days before the start of experiments. During
chronic studies raw blood pressure waveforms were recorded for
the first 10 min of each hour and BP, HR, and RR data was
recorded continuously online using the HRBP version 8 script
for Spike 2. Baseline data was recorded for 5 days before virus
injection and for a subsequent 25 days following virus injection.
BP, HR and RR data was extracted oﬄine following acute studies.
Spectral analysis of systolic BP and HR variability was performed
using HRV1 script for Spike 2 to calculate power in the very low
frequency (VLF): 0–0.3 Hz; LF: 0.3–0.8 Hz and high frequency
(HF): 0.8–3.3 Hz frequency bands (Parati et al., 1995; Japundžic´-
Žigon, 1998). The following settings were used to compute the
power spectra: time constant for DC removal: ± 3 s; frequency
range of spectra: 0–5.12 Hz; epoch duration: 25 s; FFT size: 128;
window type: Hanning. It is known that LF:HF-HRV and LF-
SBPV can be used as indirect measures of cardiac and vasomotor
sympathetic tone, respectively (Waki et al., 2006; Lozic´ et al.,
2014). Additionally, to confirm that any changes in spectral
analysis data between experimental groups was associated with
change in sympathetic nervous activity, rats were injected with
hexamethonium (i.v.; 10 mg kg−1) 20 days after virus injection,
to directly assess the relative level of tone as indicated by the
extent of the fall in arterial pressure. The change in blood
pressure following hexamethonium injection was calculated by
subtracting MABP over the 10 s period following injection
from a 10 s baseline period. BP and pulse interval waveforms
were also analyzed to assess changes in baroreflex sensitivity
(BRS; Oosting et al., 1997) using sBRG script (Spike 2, CED).
BRS values calculated over a total 24 h recording period
were averaged to provide a single value per day. All data are
presented as mean ± SEM unless otherwise stated. Statistical
analysis was carried out using Graphpad Prism 5.0 software
for Mac (Graphpad Software Inc., United States). Statistical
significance for differences between groups (n = 6) was defined
as P < 0.05. Responses following injection of pharmacological
compounds to the RVLM were compared using a 1-way analysis
of variance (ANOVA) with Tukey post-tests. Time course data
was compared using a 2-way analysis of variance (ANOVA) with
Bonferroni Post-tests. Otherwise statistical differences between
two experimental groups were evaluated using independent-
sample unpaired Student’s t-tests.
RESULTS
Upregulation of apln and aplnr
Expression in RVLM of SHR
Apln and aplnr expression levels in micropunches of RVLM from
SHR and WKY rats were quantified using qPCR (n = 4/group).
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FIGURE 1 | The apelinergic system is upregulated in SHR. Relative expression of (A) apln and (B) aplnr in RVLM micropunches from WKY (n = 4) and SHR (n = 4)
rats quantified by RT-PCR. Data shown is mean ± SEM. ∗P < 0.05, ∗∗P < 0.01. (C) Schematic illustrating the localisation of injection sites (matching dots indicate
bilateral injection sites), representative of sections from each animal group, determined by examination of the deposition of dye in the brain stem of animals. RVLM
and N. Ambiguus (N. Amb) are indicated (Adapted from Paxinos and Watson, 1998; Figure 68). (D,E), change in (D) MABP and (E) LF-SBP following microinjection
of saline, [Pyr1]apelin-13, F13A and F13A + [Pyr1]apelin-13 to the RVLM of WKY (n = 4) and SHR (n = 4) rats. Data shown is mean ± SEM. ∗∗P < 0.01,
∗∗∗P < 0.001, saline vs. [Pyr1]apelin-13; #P < 0.05, ###P < 0.001, F13A vs. [Pyr1]apelin-13; + P < 0.05, + + + P < 0.001, [Pyr1]apelin-13 vs.
F13A + [Pyr1]apelin-13; δδ P < 0.01, WKY [Pyr1]apelin-13 vs. SHR [Pyr1]apelin-13.
Both apln (P < 0.01) and aplnr (P < 0.05) transcript levels were
significantly higher in SHR in comparison with WKY control rats
(Figures 1A,B, respectively).
Effects of Acute APJ Blockade on
Cardiovascular Parameters in
Anesthetized Normotensive WKY and
Hypertensive SHR Rats
Baseline MABP was significantly increased in SHR compared to
WKY rats (130 ± 14 mmHg vs. 87 ± 3 mmHg, respectively,
P < 0.05, n = 4/group). Figure 1C shows a schematic
illustrating the localization of injection sites. Microinjection of
[Pyr1]apelin-13 (200 pmol) to the RVLM increased MABP and
LF-SBP in the RVLM of WKY (10 ± 2 mmHg, P < 0.01;
11.9 ± 3.6%, P < 0.05, respectively) and SHR (20 ± 2 mmHg,
P< 0.01, 17.2± 3.1%, P< 0.05, respectively) compared to saline-
injected controls (WKY:0.4 ± 0.3 mmHg and 0.6 ± 1.1%; SHR:
2.1± 2.2 mmHg and−0.7±−0.4%; Figures 1D,E, respectively).
The pressor response to microinjection of [Pyr1]apelin-13 in
the RVLM of SHRs was significantly greater than in WKY
(P < 0.01, Figure 1D). Microinjection of an APJ-specific
antagonist, [Ala13]-apelin-13 (F13A, 2 nmol), alone into the
RVLM had no significant effect on BP or LF-SBP in either WKY
or SHR, but abolished all [Pyr1]apelin-13-mediated increases in
BP and LF-SBP in WKY and SHR (MABP: 2 ± 1 mmHg and
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4 ± 1 mmHg, respectively, Figure 1D; LF-SBP: 0.6 ± 0.8%
and 1.9 ± 1.1% respectively, Figure 1E). Microinjection of
[Pyr1]apelin-13 into the RVLM of WKY and SHR had no
statistically significant effect on HR.
Effects of LV-APJ-shRNA Microinjection
on aplnr Expression and Function
To investigate the role of APJ in the RVLM for BP control,
lentiviral vector-mediated gene delivery was used to knockdown
aplnr in the RVLM. Immunofluorescence confocal microscopy
confirmed expression of eGFP fluorescence, and thus localization
of eGFP protein and the transgene, in the RVLM within
300 µm of the injection sites of virus-injected male WKY
rats at 25 days post-virus injection (Figure 2A), supporting
long-term expression of the transgene. qPCR analysis showed
successful knockdown of aplnr in the RVLM of rats injected
with LV-APJ-shRNA when compared with LV-scr-shRNA-
injected rats (Figure 2B; P < 0.05). LV-APJ-shRNA decreased
aplnr expression by ∼64% at day 25 post-virus injection
in punches from the RVLM of LV-APJ-shRNA-injected
rats. Additionally, to confirm APJ knockdown efficiency
in vivo, the cardiovascular responses of rats to a direct
“challenge” microinjection of [Pyr1]apelin-13 to the RVLM
were measured 25 days after virus transduction. As expected,
bilateral microinjection of [Pyr1]apelin-13 into the RVLM of
LV-scr-shRNA-injected rats elicited an increase in mean basal
BP of 10.3 ± 1.4 mmHg (Figure 2C), and these increases
were completely abrogated in LV-APJ-shRNA-injected rats
(−1.7 ± 1.4 mmHg, P < 0.01). However, microinjection
of L-glutamate, used to assess functionally the position of
the micropipette in the RVLM at the beginning of each
experiment (n = 12), caused a significant and comparable
increase in MABP in LV-scr-shRNA- and LV-APJ-shRNA-
injected rats (22.4 ± 2.1 mmHg and 24.5 ± 3.1 mmHg,
respectively; Figure 2C) when compared to saline controls
(0.1± 0.8 mmHg and−0.4± 0.8 mmHg, respectively, P< 0.001;
Figure 2C).
Effects of Chronic aplnr Knockdown in
the RVLM on Cardiovascular Parameters
in WKY Rats
Baseline physiological variables in awake normotensive WKY
rats are summarized in Table 1. No significant difference
was seen in MABP or HR between LV-APJ-shRNA- and LV-
scr-shRNA-transduced WKY groups at any time point over
the 25-day monitoring period (Figures 3A,B respectively).
Hexamethonium-induced falls in arterial pressure were similar
between the LV-APJ-shRNA- and the LV-scr-shRNA-transduced
WKY groups (Figure 3C). Body weights of LV-APJ-shRNA- and
LV-scr-shRNA-transduced WKY groups increased comparably
(46 ± 3g and 50 ± 2 g, respectively) over the 25-day monitoring
period. The effectiveness of LV-APJ-shRNA-injection was verified
with a challenge microinjection of [Pyr1]apelin-13 into the
RVLM of anesthetized WKY rats at day 25 post-virus injection,
where knockdown of apnlr prevented the increase in MABP
in response to microinjection of [Pyr1]apelin-13 (Figure 3D
FIGURE 2 | Effects of LV-APJ-shRNA microinjection on aplnr expression and
function. (A) Schematic diagram showing the anatomical location of the
RVLM in the brainstem targeted with lentivirus injections, adapted from
Paxinos and Watson (1998, Figure 68) and representative fluorescent,
photomicrographs showing eGFP expression within the RVLM of a WKY rat
25 days after virus injection. Scale bar = 500 µm. (B) Relative aplnr
expression 25 days after bilateral microinjection of either LV-scr-shRNA (dark
gray bar, n = 18) or LV-APJ-shRNA (light gray bar, n = 18) to the RVLM.
(C) Change in MABP following bilateral microinjection of saline, [Pyr1]apelin-13
(200 pmol, 100 nl−1 side−1) and glutamate (1 nmol, 100 nl−1) to the RVLM of
LV-scr-shRNA, (dark gray bars, n = 18) and LV-APJ-shRNA injected (light gray
bars, n = 18) rats. Data shown is mean ± SEM ∗∗P < 0.01, ∗∗∗P < 0.001.
P < 0.001). Additionally qPCR analysis of aplnr showed
knockdown of aplnr in the RVLM of rats injected with LV-
APJ-shRNA when compared with LV-scr-shRNA-injected rats
(Figure 3E; P < 0.05). Similarly LF-SBP, LF:HF HR and
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TABLE 1 | Baseline physiological parameters measured prior to virus injection in WKY, SHR, and L-NAME treated WKY rats.
WKY SHR L-NAME-treated
LV-scr-shRNA LV-APJ shRNA LV-scr-shRNA LV-APJ-shRNA LV-scr-shRNA LV-APJ-shRNA
DABP (mmHg) 79 ± 2 76 ± 4 101 ± 6 98 ± 5 101 ± 13 102 ± 12
SABP (mmHg) 121 ± 2 116 ± 3 160 ± 6 167 ± 11 155 ± 13 160 ± 15
MABP (mmHg) 98 ± 2 93 ± 3 130 ± 2 127 ± 5 126 ± 13 129 ± 13
PP (mmHg) 42 ± 1 40 ± 2 60 ± 1 60 ± 1 54 ± 1 57 ± 4
RR (breaths/min) 94 ± 2 86 ± 1 87 ± 2 87 ± 2 94 ± 2 93 ± 3
HR (bpm) 323 ± 4 320 ± 17 337 ± 15 324 ± 8 325 ± 14 305 ± 2
Weight (g) 261 ± 4 273 ± 9 289 ± 4 292 ± 9 233 ± 6 233 ± 5
FIGURE 3 | Effects of knockdown of aplnr on cardiovascular parameters in WKY rats. Changes in (A) MABP and (B) HR ranging from 5 days before (–5) to 25 days
after bilateral microinjection (vertical dotted line) of either LV-scr-shRNA (n = 6) or LV-APJ-shRNA (n = 6). Inset bar graphs show change in (A) MABP or (B) HR and
calculated as MABP or HR at day –5 subtracted from MABP or HR at day 24. (C) Blockade of autonomic ganglionic transmission (hexamethonium 10 mg kg−1, i.v.)
produced no difference in MABP response in LV-APJ-shRNA (n = 6) or LV-APJ-shRNA (n = 6) injected WKY. (D) Relative aplnr expression in the RVLM and (E)
change in MABP following bilateral administration of [Pyr1]apelin-13 (200 pmol) to the RVLM of LV-scr-shRNA (dark gray bar, n = 6) or LV-APJ-shRNA (light gray bar,
n = 6), 25 days after virus injection. Data shown is mean ± SEM. ∗P < 0.05, ∗∗∗P < 0.001.
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TABLE 2 | Knockdown of aplnr in the RVLM of WKY, SHR, and L-NAME treated WKY rats had no effect on LF-SBP (% total power), LF:HF HR or baroreflex sensitivity
(BRS, ms/mmHg).
LV-scr-shRNA LV-APJ-shRNA
LF-SBP (% of total power)
Baseline Day 24 Change Baseline Day 24 Change
WKY 9.43 ± 0.72 6.63 ± 0.52 −3.00 ± 1.01 9.04 ± 1.62 6.90 ± 0.70 −1.92 ± 1.25
SHR 13.68 ± 0.76 10.19 ± 0.47 −3.84 ± 0.65 12.32 ± 1.04 9.77 ± 0.69 −2.84 ± 1.55
L-NAME 8.92 ± 0.23 5.50 ± 0.26 −3.63 ± 0.29 7.34 ± 0.61 4.74 ± 0.26 −2.70 ± 0.45
LF:HF HR
Baseline Day 24 Change Baseline Day 24 Change
WKY 0.29 ± 0.08 0.27 ± 0.05 −0.02 ± 0.03 0.22 ± 0.03 0.25 ± 0.07 0.02 ± 0.05
SHR 0.22 ± 0.02 0.19 ± 0.01 −0.04 ± 0.02 0.22 ± 0.05 0.26 ± 0.09 0.04 ± 0.09
L-NAME 0.20 ± 0.01 0.21 ± 0.04 0.02 ± 0.04 0.24 ± 0.07 0.20 ± 0.01 −0.05 ± 0.07
BRS (ms/mmHg)
Baseline Day 24 Change Baseline Day 24 Change
WKY 0.60 ± 0.09 0.57 ± 0.05 0.01 ± 0.09 0.67 ± 0.03 0.63 ± 0.10 −0.02 ± 0.09
SHR 0.36 ± 0.03 0.31 ± 0.04 0.02 ± 0.02 0.42 ± 0.03 0.44 ± 0.11 0.06 ± 0.09
L-NAME 0.53 ± 0.10 0.51 ± 0.07 −0.01 ± 0.09 0.52 ± 0.07 0.37 ± 0.04 −0.14 ± 0.03
BRG were not significantly different between LV-APJ-shRNA-
and LV-scr-shRNA-transduced WKY groups at any time point
(Table 2).
Effects of Chronic aplnr Knockdown in
the RVLM on Cardiovascular Parameters
in SHR and L-NAME-Treated Rats
SHR and L-NAME-treated rats mice exhibited higher SABP,
DABP, MABP, and PP at the beginning of experiments compared
with normotensive WKY rats, while RR and HR were similar
between normotensive and hypertensive animals (Table 1). In
LV-APJ-shRNA rats MAPB and HR was unchanged compared
to rats receiving LV-scr-shRNA; this was the case in both
SHR (Figures 4A,B) and L-NAME-treated rats (Figures 5A,B).
No change was seen in hexamethonium-induced falls in
arterial pressure between the LV-APJ-shRNA- and the LV-scr-
shRNA-transfected SHR or L-NAME groups (Figures 4C, 5C
respectively). No significant difference was seen in body weights
between the LV-APJ-shRNA- and LV-scr-shRNA-transduced
SHR (LV-APJ-shRNA: 32 ± 3g; LV-scr-shRNA: 32 ± 4g,
P > 0.05) or L-NAME (LV-APJ-shRNA: 40 ± 10g; LV-scr-
shRNA: 47 ± 3g, P > 0.05) groups over the 25-day monitoring
period.
A subsequent challenge microinjection of [Pyr1]apelin-13 into
the RVLM at day 25 post LV-APJ-shRNA injection resulted in
a significantly reduced response in MABP in both anesthetized
SHR and L-NAME-treated rats (Figures 4D, 5D). Additionally
qPCR analysis of aplnr showed knockdown of aplnr in the RVLM
of rats injected with LV-APJ-shRNA when compared with LV-
scr-shRNA-injected rats (Figures 4, 5E; P < 0.01 and P < 0.05,
respectively). Similarly no significant differences were seen in
LS-SBP, LF:HF HR and BRG between LV-APJ-shRNA- and
LV-scr-shRNA-transduced SHR and L-NAME-treated groups
(Table 2).
APJ in the Development of Hypertension
in Pre-hypertensive Juvenile SHR
To attenuate the expression of aplnr in pre-hypertensive SHR,
LV-APJ-shRNA was microinjected into juvenile 4-week-old SHRs
immediately prior to the crucial period between 4 and 8 weeks of
age when hypertension develops (Dickhout and Lee, 1998). As
evidenced using tail-cuff BP measurements, the progression of
hypertension in SHRs treated with LV-APJ-shRNA was similar to
animals microinjected with control LV-scr-shRNA (Figure 6A),
showing increased levels of BP characteristic of untreated
SHR. Aplnr knockdown by LV-APJ-shRNA transduction was
confirmed, at the end of the experiment, by the decreased
expression of aplnr in the RVLM (Figure 6B) and the lack of
response to microinjection of [Pyr1]apelin-13 in the RVLM when
compared to the increase in MABP observed in response to
microinjection of [Pyr1]apelin-13 in LV-scr-shRNA-transduced
rats (Figure 6C).
DISCUSSION
Chronic sympathetic hyperactivity is present in a significant
percentage of patients with essential hypertension, responsible
for 95% of all hypertensive disorders (Carretero and Oparil,
2000), but the causative mechanisms remain unclear. The RVLM
is a major brain region involved in the regulation of SNA
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FIGURE 4 | Effects of knockdown of aplnr on cardiovascular parameters in SHRs. Changes in (A) MABP and (B) HR ranging from 5 days before (–5) and 25 days
after bilateral microinjection (vertical dotted line) of either LV-scr-shRNA (n = 6) or LV-APJ-shRNA (n = 6). Inset bar graphs show change in (A) MABP or (B) HR
calculated as MABP or HR at day –5 subtracted from MABP or HR at day 24. (C) Blockade of autonomic ganglionic transmission (hexamethonium 10 mg kg−1, i.v.)
produced a no difference in MABP response in LV-scr-shRNA (n = 6) or LV-APJ-shRNA (n = 6) injected SHR. (D) Relative aplnr expression in the RVLM and (E)
change in MABP following bilateral administration of [Pyr1]apelin-13 (200 pmol) to the RVLM of LV-scr-shRNA (dark gray bar, n = 6) or LV-APJ-shRNA (light gray bar,
n = 6), 25 days after virus injection. Data shown is mean ± SEM. ∗∗P < 0.01.
associated with cardiovascular function, and recent work has
shown that bilateral microinjection of [Pyr1]apelin-13 into this
region increases sympathetic vasomotor tone and BP (Zhang
et al., 2009). We hypothesized therefore, that APJ signaling in the
RVLM may contribute to the development of hypertension. Our
study however, examining the physiological outcome of chronic
knockdown of aplnr in the RVLM on cardiovascular regulation in
conscious, unrestrained, WKY, SHR, or L-NAME-treated WKY
rats, reveals that MABP and SNA is similar with or without the
integrity of aplnr. These results indicate that chronic decreased
aplnr expression in the RVLM does not influence endogenous
apelin-mediated MABP or sympathetic vasomotor drive in these
normotensive and hypertensive rodents. Additionally we show
that knockdown of aplnr in the RVLM of pre-hypertensive SHR
does not prevent or delay the age-dependent development of
hypertension in the SHR. Thus, apelin activation of APJ does not
appear to have a role to play in the genesis or maintenance of
hypertension in the animal models used in this study.
A recent study has suggested that apelin levels are enhanced
in the RVLM of hypertensive SHR, and additionally, that
overexpression of apln in the RVLM of WKY rats by gene
transfer chronically increases MABP (Zhang et al., 2009).
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FIGURE 5 | Effects of knockdown of aplnr on cardiovascular parameters in L-NAME treated WKY rats. Changes in (A) MABP and (B) HR ranging from 5 days before
(–5) and 25 days after bilateral microinjection (vertical dotted line) of either LV-scr-shRNA (n = 6) or LV-APJ-shRNA (n = 6). Inset bar graphs show change in
(A) MABP or (B) HR calculated as MABP or HR at day –5 subtracted from MABP or HR at day 24. (C) Blockade of autonomic ganglionic transmission
(hexamethonium 10 mg kg−1, i.v.) produced a no difference in MABP response in LV-scr-shRNA (n = 6) or LV-APJ-shRNA (n = 6) injected SHR. (D) Relative aplnr
expression in the RVLM and (E) change in MABP following bilateral administration of [Pyr1]apelin-13 (200 pmol) to the RVLM of LV-scr-shRNA (dark gray bar, n = 6)
or LV-APJ-shRNA (light gray bar, n = 6), 25 days after virus injection. Data shown is mean ± SEM. ∗P < 0.05, ∗∗P < 0.01.
However, although apelin has been thought to contribute to the
establishment of hypertension (Seyedabadi et al., 2002; Chandra
et al., 2011; Zhu et al., 2013), the importance of the apelinergic
system in influencing SNA and arterial BP is unclear. Recent
work by Zhang et al. (2014) indicates that both apelin and
APJ gene and protein expression are up-regulated in the PVN
in SHR, and that pharmacological inhibition of APJ following
microinjection of the APJ-specific antagonist F13A in the PVN
decreases SNA and BP in SHR. These observations suggest that
APJ in the PVN contributes to hypertension via modulation
of sympathetic activation. In the present study we confirm the
finding of Zhang et al. (2009) showing an enhanced expression
of apln in the RVLM of SHR, and furthermore we show a
significant upregulation of aplnr in the RVLM of this model
of hypertension, in comparison to WKY rats. Additionally we
show a greater acute MABP response to the microinjection of
[Pyr1]apelin-13 in the RVLM of SHR than that seen in WKY
rats, reinforcing the premise that an augmented expression of
the apelinergic system in the RVLM of hypertensive animals
may have a role to play in influencing MABP and sympathetic
vasomotor tone.
The possible role of APJ in cardiovascular regulation has
been investigated primarily in acute (<30 min) experimental
conditions in anesthetized animals (Seyedabadi et al., 2002;
Mitra et al., 2006; Zhang et al., 2009), and in the present
study we have corroborated these studies and have shown
that acute activation of APJ by exogenous administration of
[Pyr1]apelin-13 into the RVLM increases MABP and SNA,
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FIGURE 6 | Effects of knockdown of aplnr in pre-hypertensive SHR. (A) Changes in MABP in juvenile SHR after bilateral microinjection of either LV-scr-shRNA (n = 6)
or LV-APJ-shRNA (n = 6) at 4 weeks. Inset bar graph shows change in MABP calculated as MABP at 5 weeks subtracted from MABP at 10 weeks. (B) Relative
aplnr expression in the RVLM and (C) change in MABP following bilateral administration of [Pyr1]apelin-13 (200 pmol) to the RVLM of LV-scr-shRNA (dark gray bar,
n = 6) or LV-APJ-shRNA (light gray bar, n = 6) 6 weeks after virus injection. Data shown is mean ± SEM. ∗P < 0.05, ∗∗∗P < 0.001.
as measured by spectral analysis, in SHR and WKY rats.
Administration of the APJ antagonist, F13A, into the RVLM
prevented [Pyr1]apelin-13-induced increases in MABP in both
SHR and WKY rats, thus suggesting a role for APJ in MABP
regulation. However, administration of F13A alone had no
significant effect on MABP in SHR, showing that, despite the
upregulation of apln and aplnr in the RVLM of SHR, there
is no tonic (i.e., endogenous) activation of APJ in the RVLM
contributing to MABP in these animals. F13A administration
alone in the RVLM also had no significant effect on MABP
and SNA in WKY rats. This is consistent with our previous
acute study in the RVLM of normotensive Wistar rats (Griffiths
et al., 2017) but is inconsistent with previous studies where
injection of an apelin-neutralizing antibody into the RVLM
significantly decreased BP in SHR (Zhang et al., 2009), or with
a study in the PVN where APJ was shown to contribute to
both tonic sympathetic activity and to SNA and BP increases
induced by PVN-apelin-13-microinjection in SHR (Zhang et al.,
2014).
Following on from our acute studies, our purpose was to
chronically knockdown aplnr expression in RVLM neurons and
to evaluate the resultant consequences upon long-term SNA
and BP regulation in conscious normotensive and hypertensive
rats. To that end, for the first time to our knowledge, a LV-
APJ-specific shRNA construct (LV-APJ-shRNA) was generated
that was shown to successfully obliterate the APJ RVLM pressor
response to apelin in vivo after microinjection into the RVLM.
Immunofluorescence confocal microscopy confirmed expression
of the LV-APJ-shRNA transgene in the RVLM in microinjected
rats. Additionally, in all experimental groups, the injection of LV-
APJ-shRNA to the RVLM successfully blocked the MABP and
SNA effects of exogenously applied [Pyr1]apelin-13, confirming
long-term aplnr knockdown in the RVLM that results in a high
efficacy of silencing of [Pyr1]apelin-13-mediated APJ pressor
effects, and indicating that the cardiovascular effects of exogenous
apelin are mediated specifically via activation of APJ. Thus we are
confident that APJ in the RVLM has been successfully targeted in
our studies.
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Our results show that chronic decreased aplnr expression in
the RVLM of WKY, SHR, or L-NAME-treated WKY rats after LV-
APJ-shRNA microinjection did not result in sympathoinhibition,
or in a significant decrease in MABP, or in HR, when
compared to control LV-scr-shRNA-injected rats. It must be
noted that our studies of SNA changes are indirect and based
on spectral analysis. However, injection of hexamethonium
produced a similar fall in arterial pressure in LV-APJ-shRNA-
transfected animals compared with LV-scr-shRNA-transfected
animals across all experimental groups, suggesting that the
basal level of sympathetic vasomotor tone was unchanged by
knockdown of aplnr expression and APJ activity. We do not
know the extent to which changes in aplnr expression are
mirrored at the protein level - however, if residual APJ protein
is present following chronic aplnr knockdown it is not sufficient
to elicit a cardiovascular response to exogenously applied apelin.
Our results indicate that, in agreement with our acute studies,
endogenous APJ activity in the RVLM is not involved in the
long-term tonic control of SNA and BP in conscious WKY, SHR
or L-NAME-treated WKY rats. We also investigated whether
attenuation of the expression of aplnr, and thus levels of
functional APJ protein, in the RVLM of pre-hypertensive SHR
disrupts the development of hypertension. BP has been shown
to begin to diverge between SHR and WKY rats at 4 weeks
of age (Dickhout and Lee, 1998). However, the development of
hypertension in juvenile SHR treated with LV-APJ-shRNA at 4
weeks of age, as evidenced using tail-cuff BP measurements, was
comparable to LV-scr-shRNA-injected rats and was characteristic
of levels seen in control SHR. These results indicate that chronic
aplnr knockdown conducted at a pre-hypertensive age had no
role in the onset or eventual degree of hypertension in SHR, and
did not delay age-dependent progression of hypertension.
As the lentivirus microinjection in our study clearly targets the
RVLM and blocks APJ functional activity, possible explanations
for the discrepancies between our results and those of other
studies may be the conscious state of the animals, different
effects of the apelin isoforms used, or may be a reflection
of the regions studied (PVN vs. RVLM). Acute studies used
anesthetized rats whereas in contrast our chronic study was
conducted in conscious, unrestrained rats. It is well documented
that anesthesia modifies cardiovascular responses mediated via
SNA (Lake et al., 1997), and conflicting results about the role
of peripheral apelin in regulating vascular tone have been
suggested to depend on the presence or absence of anesthesia
- in anesthetized intact rats peripherally injected apelin has a
hypotensive action (Lee et al., 2000; Reaux et al., 2001; Mitra
et al., 2006), but has no consistent effect in awake, unrestrained
rats (Kagiyama et al., 2005; Mitra et al., 2006). However, our
chronic studies in conscious animals are in agreement with our
acute results in anesthetized rats, indicating no contribution of
endogenous apelin in the RVLM to hypertension via activation
of SNA and MABP. It is of note that physiological findings
(e.g., on BP control, cardiac homeostasis) in apln and aplnr
KO mice have suggested that another endogenous APJ ligand,
or additional apelin receptors may exist (Kuba et al., 2007;
Charo et al., 2009). Therefore we cannot discount (1) that some
unidentified endogenous ligand may be acting at residual APJ,
remaining in the RVLM after LV-APJ-shRNA microinjection,
to elicit a cardiovascular response or (2) that apelin may act
at a receptor other than APJ in the RVLM to contribute to
elevated SNA and BP in WKY, SHR, or L-NAME-treated WKY
rats. It remains possible that the pressor effect of apelin may
originate, in part, from its effects on the PVN or from other brain
regions.
Apelin/APJ is upregulated in a number of
(patho)physiological conditions including chronic heart failure
(Földes et al., 2003), hypoxia (Geiger et al., 2011), insulin and
obesity (Boucher et al., 2005; Geurts et al., 2011), exercise (Zhang
et al., 2006) and stress (O’Carroll et al., 2003). However, despite
the fact that aplnr (and apln) gene expression is upregulated in
the RVLM of SHR, it does not appear to be coupled to the tonic
control of MABP. Increased aplnr/apln expression in the RVLM
does not automatically reflect increased APJ and apelin protein
levels in this region - the increase in RVLM transcripts may
result in increased APJ and apelin at sites distal to the RVLM, on
projecting axon terminals, and not within the RVLM itself. It will
be critical in future studies to determine whether the increase in
RVLM aplnr/apln is associated with an increase in APJ/apelin
protein. Additionally, it should be noted that an increase in
receptor density in itself does not necessarily equate to a change
in receptor sensitivity and/or functional responses (Larsson
et al., 1989). It is also possible that this transcript upregulation
is an indirect result of changes in other transmitter systems, that
project to or are inherent to the RVLM, and that these changes
override any contribution of the apelinergic system to the
maintenance of MABP. BP regulation is a complex physiological
function dependent on the interaction between a broad range of
chemical mediators including local endothelial-derived factors
and the cardiovascular, neural and renal-endocrine systems
(Chopra et al., 2011). Previous studies in other receptor systems
have shown compensatory changes in gene expression following
injection of gene-specific lenti- or adenoviral constructs (Chen
et al., 2006; Blume et al., 2013). APJ interacts with other
receptors to regulate the cardiovascular system (Gurzu et al.,
2006; Rostamzadeh et al., 2017, 2018), and forms heterodimers
in vitro with other GPCRs e.g., the angiotensin II receptor (Chun
et al., 2008), the kappa opioid receptor (Li et al., 2012), the
neurotensin 1 receptor (Bai et al., 2014a) and the bradykinin
1 receptor (Bai et al., 2014b), to selectively regulate cellular
responses mediated by apelin. It is tempting to speculate that
the V1a vasopressin receptor (V1aR), a key modulator of
cardiovascular regulation (Japundžic´-Žigon, 2013), might be
capable of forming heterodimers with APJ. Apelin and APJ have
been described as counter-regulators of the vasopressinergic
system and, in the hypothalamo-neurohypophysial system, the
physiological effects of apelin appear to be mediated through
modulation of vasopressin neuron activity and secretion (Reaux
et al., 2001; Taheri et al., 2002; De Mota et al., 2004; Reaux-Le
Goazigo et al., 2004; Tobin et al., 2008). Both APJ and V1aRs
are expressed in the RVLM (Kc et al., 2010) and moreover,
we have shown that [Pyr1]apelin-13 acts as a modulating
neurotransmitter in the normotensive RVLM, interacting with
the V1aR to affect vascular tone, thus indicating an interplay
between the apelinergic and vasopressinergic systems at the level
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of the RVLM (Griffiths et al., 2017). Conceivably APJ and V1aR
may interact to regulate cardiovascular function, and a loss of APJ
activity within the RVLM may influence the expression or cellular
signaling of V1aR to cause homeostatic adaptation. However,
such a direct functional relationship of APJ with V1aR, or any
other receptor system, requires further evaluation.
In summary, our data establish that aplnr in the RVLM
does not play a role in the maintenance or development
of chronic elevated BP in the SHR genetic model of high
BP, or in L-NAME-treated WKY rats. A long-term BP
regulatory function for APJ may become apparent only in
other pathophysiological conditions and it remains to be
established whether APJ may play a critical role in other
models of hypertension such as deoxycorticosterone acetate-
salt, that activates both the vasopressinergic and sympathetic
nervous systems, or angiotensin II-induced hypertensive
rats.
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